Welcome to Amayeza Information Centre



COVID-19 Outbreak

Please note that Amayeza will continue to provide our usual services during the period of lockdown.

If you are not able to reach us telephonically you can contact us via e-mail at:

vaccines@amayeza-info.co.za for questions on vaccines

Amayeza@amayeza-info.co.za for our subscribers who have medicine information enquiries

Fax to email: 086 664 6868

Alternatively, you may contact us via the Vula App available from your app store. For instructions, click here.

 The word “Amayeza” means “Medicine” in the Xhosa language.

We are an independant medicine information centre that aims to provide reliable, accurate, objective, and up-to-date information on medicine to pharmacists and other health care professionals across South Africa.

Please note that our services are subscription-based. In order for you to benefit from our up-to-date medicine information, you will need to be a subscriber of Amayeza Information Services. For more information regarding subscriptions, click here




Vaccine schedules and records

You can now print the childhood immunisation record(s). Click on the relevant link to download:


COVID-19 Outbreak Information

**Click here for Guidance on routine childhood immunisations during the COVID-19 pandemic

**BCG vaccination and COVID-19

There has been a substantial amount of media attention to the BCG vaccine preventing COVID-19 – click here for more information:

World Health Organization (WHO) statement

South African Health Products Regulatory Authority (SAHPRA) statement

**Use of immunoglobulin preparations for prevention of COVID-19

The following information has been provided courtesy of the Allergy Society of South Africa (ALLSA):

Position statement on ineffective and inappropriate use of plasma-derived IgG preparations to prevent SARS-CoV-2 infection
Appeal by ALLSA (Allergy Society of South Africa) and PIDDSA (the Primary Immunodeficiency Working Group of ALLSA) for DOH and SAHPRA to prevent the inappropriate use of plasma derived IgG for prevention or treatment of SARS-CoV-2 infections

Plasma derived IgG (e.g. Polygam®, Intragam® & Beriglobin®) for immunoglobulin replacement therapy (IRT) is a limited resource which is essential and life-saving for patients living with primary and secondary immunodeficiency. Whilst IRT provides protection against a wide range of infections, no current immunoglobulin product contains anti-SARS-CoV-2 specific antibodies, hence it does not confer immunity against coronavirus.

  1. IRT, at any dose or route of injection (intramuscular, subcutaneous or intravenously) should not be used by the general population as an “immune booster” against COVID-19.
  1. Although patients with certain immunodeficiencies already receiving IRT may be at increased risk of infection or severe COVID-19 disease, there is no evidence to date that more frequent or higher dosing of immunoglobulin will offer more protection.
  1. For patients with primary or secondary immunodeficiency whose condition does not require regular IRT, there is no need to start immunoglobulin therapy due to the risk of COVID-19.

ALLSA and PIDDSA are deeply concerned about the current inappropriate use of plasma derived IgG as an immune booster against SARS-CoV-2 and the consequences that stock shortages of these products will hold for patients in real need who have no alternative therapy.

ALLSA and PIDDSA call on regulatory bodies and prescribers for the judicious use of plasma-derived IgG at this time of the COVID-19 outbreak to ensure against stock shortages and any unnecessary morbidity or loss of life.

**Stay up-to-date and well-informed about the current COVID-19 outbreak with the National Institute for Communicable Diseases (NICD).

COVID-19 Poster

Clinical management of suspected or acute COVID-19

Hand_Sanitiser_Poster Handwashing_poster






With the approach of the holiday season in December, it is important for travellers visiting any of the malaria areas within southern Africa or elsewhere to take appropriate precautions and maintain a high index of
suspicion for symptoms of malaria on their return.







Archived information 



Useful links:




Data Privacy Statement

Amayeza Information Services stores any personal information to enable us to address the enquiry, or other such matters that have been raised, and to document our response. The information will be retained in a secure server and will only be used for this purpose, unless required for legal proceedings. If reporting an adverse event, the information provided will be used in order to meet regulatory requirements in relation to the safety of medicines. In accordance with applicable law, you may have a right to access and correct your information. If you would prefer that Amayeza does not store your personal data, please let us know.



Last updated: 09 April 2020

Comments are closed.